Supriya Lifescience Limited (NSEI: SUPRIYA)
Health Care · Pharmaceuticals · IN
Rs847.65
-8.95% today · +16.9% 1Y
Supriya Lifescience Limited (NSEI: SUPRIYA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $704.91M and employs 607 people.
Over the last twelve months the share price has gained 16.9%, trading between 545.50 and 1.08K.
Tweenvest scores Supriya Lifescience Limited across four factors: quality 81/100, value 50/100, growth 90/100, dividend 61/100. Its strongest factor is growth.
SUPRIYA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $704.91M
- Revenue (TTM)
- $92.28M
- P/E
- 34.38
- EPS
- 24.65
- Dividend yield
- 0.12%
- Beta (5Y)
- 0.63
- 52-week high
- Rs1,085.00
- 52-week low
- Rs545.50
- Avg volume (3M)
- —
- Shares outstanding
- 80.48M
- Employees
- 607
- Next earnings
- —
About Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
- ISIN
- INE07RO01027
- Founded
- 1987
- Listed since
- Dec 28, 2021
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Fuan Pharmaceutical (Group) Co., Ltd.SZSE: 300194 | $715.81M | CN¥4.03 | +3.60% |
| China Shineway Pharmaceutical Group LimitedSEHK: 2877 | $714.72M | HK$7.43 | +1.16% |
| Nxera Pharma Co., Ltd.TSE: 4565 | $710.97M | ¥1,232.00 | +0.98% |
| Bliss GVS Pharma LimitedBSE: 506197 | $708.15M | Rs644.55 | -5.80% |
| Sanofi India LimitedBSE: 500674 | $700.94M | Rs2,945.55 | -2.84% |
| Hunan Fangsheng Pharmaceutical Co., Ltd.SHSE: 603998 | $696.83M | CN¥10.63 | +2.61% |
| Jiangsu Lianhuan Pharmaceutical Co., Ltd.SHSE: 600513 | $693.81M | CN¥16.28 | +7.89% |
| Genomma Lab Internacional, S.A.B. de C.V.BMV: LAB B | $691.79M | MX$13.04 | +1.95% |
Figures last refreshed Oct 11, 2026.